Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: PR Newswire
Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc.VANCOUVER, Oct. 21, 2025 /PRNewswire/ -- Equity Insider News Commentary – Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms, leaving millions with conditions that traditional pharma cannot cure. New FDA guidances from October 2025 outline streamlined approval pathways for cell and gene therapies targeting severe conditions in small populations[1], signaling regulatory momentum toward advanced platforms that replace, repair, or modify disease-causing genes rather than simply managing symptoms. These companies represent a new generation of biotechs pursuing targeted solutions where traditional drugs have reached their limits: Avant Technologies, Inc. (OTCQB: AVAI), Lexeo Therapeutics, Inc. (NASDAQ: LXEO), Moleculin Biotech, Inc. (NASDAQ: MBRX), Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), and Fractyl Health, Inc. (NASDAQ: GUTS).According to Precedence Res
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]Seeking Alpha
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Acadia to pivot to Alzheimer's psychosis pipeline, accd to Wall Street analysts [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $29.00 price target on by analysts at Mizuho.MarketBeat
- Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
ACAD
Earnings
- 11/5/25 - Beat
ACAD
Sec Filings
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- 11/14/25 - Form SCHEDULE
- ACAD's page on the SEC website